Just three months out from the legalisation of psychedelic medicines for mental health treatment, questions remain among experts about exactly how the drugs will be administered.
In February the Therapeutic Goods Administration (TGA) announced that MDMA and psilocybin — the active ingredient in magic mushrooms — would be reclassified in July to allow them to be prescribed by psychiatrists to treat patients with post-traumatic stress disorder and treatment-resistant depression.
